Quick Answer
CAPRICOR THERAPEUTICS, INC. reported Cash and Equivalents of $287.85 million for fiscal year 2025.
CAPRICOR THERAPEUTICS, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $287.85M | +2450.3% |
| 2024 | $11.29M | -23.2% |
| 2023 | $14.69M | +53.0% |
| 2022 | $9.60M | -72.5% |
| 2021 | $34.89M | +6.8% |
| 2020 | $32.67M | +737.7% |
| 2019 | $3.90M | -8.5% |
| 2018 | $4.26M | -30.6% |
| 2017 | $6.14M | +91.6% |
| 2016 | $3.20M | -42.5% |
| 2015 | $5.57M | -30.7% |
| 2014 | $8.03M | +364.6% |
| 2013 | $1.73M | +916.7% |
| 2012 | $170.1K | -89.0% |
| 2011 | $1.55M | -54.1% |
| 2010 | $3.38M | +6.4% |
| 2009 | $3.18M | — |
| 2005 | $0.00 | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $19.51M | -71.5% | -16.1% |
| June 30, 2025 | $23.24M | +117.4% | -19.3% |
| March 31, 2025 | $28.79M | +363.3% | +155.1% |
| December 31, 2024 | $11.29M | -23.2% | -83.5% |
| September 30, 2024 | $68.38M | +661.0% | +539.7% |
| June 30, 2024 | $10.69M | +8.7% | +72.0% |
| March 31, 2024 | $6.21M | -41.4% | -57.7% |
| December 31, 2023 | $14.69M | +53.0% | +63.6% |
- CAPRICOR THERAPEUTICS, INC. showed an increase of +2450.3% in Cash and Equivalents compared to the prior fiscal year.
- The most recent figure is from CAPRICOR THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: